Posted by Pivalde on YMB!
Donepezil decreases hippocampus atrophy rate but does not improve cognition
Alzheimers Dement. 2015 Jan 14. pii: S1552-5260(14)02856-8. doi: 10.1016/j.jalz.2014.10.003. [Epub ahead of print]
Donepezil decreases annual rate of hippocampal atrophy in suspected prodromal Alzheimer's disease.
Dubois B1, Chupin M2, Hampel H3, Lista S4, Cavedo E4, Croisile B5, Tisserand GL5, Touchon J6, Bonafe A6, Ousset PJ7, Ait Ameur A8, Rouaud O9, Ricolfi F9, Vighetto A5, Pasquier F10, Delmaire C11, Ceccaldi M12, Girard N12, Dufouil C13, Lehericy S14, Tonelli I15, Duveau F15, Colliot O2, Garnero L2, Sarazin M3, Dormont D16; “Hippocampus Study Group”.
To study the effect of donepezil on the rate of hippocampal atrophy in prodromal Alzheimer's disease (AD).
METHODS:
A double-blind, randomized, placebo-controlled parallel group design using donepezil (10 mg/day) in subjects with suspected prodromal AD. Subjects underwent two brain magnetic resonance imaging scans (baseline and final visit). The primary efficacy outcome was the annualized percentage change (APC) of total hippocampal volume (left + right) measured by an automated segmentation method.
RESULTS:
Two-hundred and sixteen only subjects were randomized across 28 French expert clinical sites. In the per protocol population (placebo = 92 and donepezil = 82), the donepezil group exhibited a significant reduced rate of hippocampal atrophy (APC = -1.89%) compared with the placebo group (APC = -3.47%), P smaller than .001. There was no significant difference in neuropsychological performance between treatment groups.
CONCLUSIONS:
A 45% reduction of rate of hippocampal atrophy was observed in prodromal AD following 1 year of treatment with donepezil compared with placebo. Less
Sort: Newest | Oldest | Most Replied Collapse all replies
- interestingtome • 3 minutes 41 seconds ago RemoveTHANK YOU Pivalde. HA reduction rate in prodromal cohort but no cognition improvement after one year, so it’s not only PBT2 that has this issue. The connection between HA atrophy and cognition is clear in the literature – I think you just need to look over long enough period of time with the right assessment methods.
- Forums
- ASX - By Stock
- ATH
- Donepezil decreases hippocampus atrophy rate but does not improve cognition
Donepezil decreases hippocampus atrophy rate but does not improve cognition
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATH (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.5¢ |
Change
0.001(25.0%) |
Mkt cap ! $26.19M |
Open | High | Low | Value | Volume |
0.5¢ | 0.5¢ | 0.5¢ | $27.94K | 6.050M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
46 | 57663299 | 0.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.5¢ | 56205001 | 43 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
46 | 57663299 | 0.004 |
74 | 84174813 | 0.003 |
19 | 29345125 | 0.002 |
15 | 81865101 | 0.001 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.005 | 56205001 | 43 |
0.006 | 17905330 | 28 |
0.007 | 9388861 | 18 |
0.008 | 7693109 | 15 |
0.009 | 4646078 | 9 |
Last trade - 16.10pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
0.5¢ |
  |
Change
0.001 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
0.5¢ | 0.5¢ | 0.5¢ | 20524121 | ||
Last updated 15.46pm 29/03/2024 ? |
Featured News
ATH (ASX) Chart |
The Watchlist
BGD
BARTON GOLD HOLDINGS LIMITED
Alex Scanlon, Managing Director & CEO
Alex Scanlon
Managing Director & CEO
SPONSORED BY The Market Online